116 related articles for article (PubMed ID: 6936573)
21. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.
Nathan CF; Kaplan G; Levis WR; Nusrat A; Witmer MD; Sherwin SA; Job CK; Horowitz CR; Steinman RM; Cohn ZA
N Engl J Med; 1986 Jul; 315(1):6-15. PubMed ID: 3086725
[TBL] [Abstract][Full Text] [Related]
22. HLA segregation of tuberculoid leprosy: confirmation of the DR2 marker.
van Eden W; de Vries RR; Mehra NK; Vaidya MC; D'Amaro J; van Rood JJ
J Infect Dis; 1980 Jun; 141(6):693-701. PubMed ID: 6156220
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies on dermal granulomas of human leprosy: characterization of cells using monoclonal antibodies.
Narayanan RB; Girdhar BK; Lavania RK; Sengupta U
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):268-72. PubMed ID: 3088184
[TBL] [Abstract][Full Text] [Related]
24. Human leukocyte antigens in forms of leprosy among Japanese patients.
Joko S; Numaga J; Kawashima H; Namisato M; Maeda H
Int J Lepr Other Mycobact Dis; 2000 Mar; 68(1):49-56. PubMed ID: 10834069
[TBL] [Abstract][Full Text] [Related]
25. T cell subsets in leprosy lesions: in situ characterization using monoclonal antibodies.
Narayanan RB; Bhutani LK; Sharma AK; Nath I
Clin Exp Immunol; 1983 Mar; 51(3):421-9. PubMed ID: 6342880
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte transformation test in lepromatous leprosy patients and their healthy siblings.
Sengupta SR; Yemul VL; Dhole TN
Lepr India; 1983 Apr; 55(2):261-4. PubMed ID: 6579324
[TBL] [Abstract][Full Text] [Related]
27. Natural suppressor cells in human leprosy: the role of HLA-D-identical peripheral lymphocytes and macrophages in the in vitro modulation of lymphoproliferative responses.
Nath I; Van Rood JJ; Mehra NK; Vaidya MC
Clin Exp Immunol; 1980 Nov; 42(2):203-10. PubMed ID: 6451335
[TBL] [Abstract][Full Text] [Related]
28. Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy.
Narayanan RB; Laal S; Sharma AK; Bhutani LK; Nath I
Clin Exp Immunol; 1984 Mar; 55(3):623-8. PubMed ID: 6423326
[TBL] [Abstract][Full Text] [Related]
29. Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin.
Narayanan RB; Bhutani LK; Sharma AK; Nath I
Indian J Lepr; 1984; 56(3):532-9. PubMed ID: 6597212
[TBL] [Abstract][Full Text] [Related]
30. Monocytes of distinct clinical types of leprosy are differentially activated by cross-linking class II HLA molecules to secrete IL-12.
Ohyama H; Kato N; Takeuchi K; Soga Y; Uemura Y; Nishimura F; Matsushita S
APMIS; 2004; 112(4-5):271-4. PubMed ID: 15233642
[TBL] [Abstract][Full Text] [Related]
31. HLA antigen and susceptibility to leprosy.
Nakajima S; Kobayashi S; Nohara M; Sato S
Int J Lepr Other Mycobact Dis; 1977; 45(3):273-7. PubMed ID: 562857
[TBL] [Abstract][Full Text] [Related]
32. The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey. A preliminary study.
Cem Mat M; Yazici H; Ozbakir F; Tüzün Y
Int J Dermatol; 1988 May; 27(4):246-7. PubMed ID: 3391713
[TBL] [Abstract][Full Text] [Related]
33. Association of leprosy with HLA-DR2 in a Southern Brazilian population.
Visentainer JE; Tsuneto LT; Serra MF; Peixoto PR; Petzl-Erler ML
Braz J Med Biol Res; 1997 Jan; 30(1):51-9. PubMed ID: 9222403
[TBL] [Abstract][Full Text] [Related]
34. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components.
Ottenhoff TH; Converse PJ; Gebre N; Wondimu A; Ehrenberg JP; Kiessling R
Eur J Immunol; 1989 Apr; 19(4):707-13. PubMed ID: 2659369
[TBL] [Abstract][Full Text] [Related]
35. The incidence of HLA antigens in leprosy.
Youngchaiyud U; Chandanayingyong D; Vibhatavanija T
Vox Sang; 1977; 32(6):342-5. PubMed ID: 898832
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemistry in histoid leprosy.
Kontochristopoulos GJ; Aroni K; Panteleos DN; Tosca AD
Int J Dermatol; 1995 Nov; 34(11):777-81. PubMed ID: 8543410
[TBL] [Abstract][Full Text] [Related]
37. HLA and leprosy in the pre and postgenomic eras.
Geluk A; Ottenhoff TH
Hum Immunol; 2006 Jun; 67(6):439-45. PubMed ID: 16728267
[TBL] [Abstract][Full Text] [Related]
38. Levamisole in the treatment of E.N.L. in leprosy.
Dharmendra
Indian J Lepr; 1985; 57(1):1-10. PubMed ID: 3897402
[No Abstract] [Full Text] [Related]
39. HLA and leprosy in Koreans.
Kim SJ; Choi IH; Dahlberg S; Nisperos B; Kim JD; Hansen JA
Tissue Antigens; 1987 Mar; 29(3):146-53. PubMed ID: 3603547
[TBL] [Abstract][Full Text] [Related]
40. HLA class-II immune response genes and products in leprosy.
de Vries RR; van Eden W; Ottenhoff TH
Prog Allergy; 1985; 36():95-113. PubMed ID: 3918314
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
